The Life of a TJR The stages of regulating and monitoring a total joint replacement

Now and the future



Amie Smirthwaite

&

Keith Tucker





WHAT WE ARE DISCUSSING TODAY......

WHAT WILL A MANUFACTURER HAVE TO DO IN THE FUTURE TO OBTAIN A

CE MARK?











DECLARATION OF INTERESTS KEITH TUCKER

Consultant Orthopaedic Surgeon. President BHS 2007-8

Chair Beyond Compliance advisory group and ODEP

Past Member NJR Steering Committee.

Member NJR Implant performance committee,

In the past I received monies from J&J for being a co-designer of 4 hip replacement implants.

All royalties were paid into a research fund

I hold stock in Accentus Medical I do not receive any financial reward for NJR, MHRA BEYOND COMPLIANCE or ODEP work. My travel expenses are reimbursed.

3RUSSELS 2018







WHERE I STARTED

- BOA REPRESENTATIVE TO MDA 1986
- JUST AFTER CE MARKS WERE INTRODUCED
- MDA HAD JUST BECOME THE COMPETENT AUTHORITY
- WHAT ABOUT PMS I ASKED
- YOU WILL HAVE TO CHANGE EU LAW IF YOU WANT THAT!!







WHY AM I HERE

- I AM A SURGEON AND HAVE SEEN THE RESULTS OF BAD IMPLANTS
- SURGEONS DO NOT WANT TO USE BAD IMPLANTS
- SURGEONS WANT TO BE SURE THAT THE REGULATIONS ARE THE BEST THEY CAN BE
- MANY SURGEONS ARE PREPARED TO HELP WITH THE INTRODUCTION OF NEW IMPLANTS
- MOST OF US ARE PASSIONATE ABOUT THESE ISSUES








WHERE WE ARE

- POST CE
- POST MOVING TJRS FROM 2b to 3
- WE HAVE AN OPPORTUNITY OF GETTING IT RIGHT THIS TIME
- THE NEW REGULATIONS
- THERE ARE NOW > 2 MILLION TJRS INSERTED THROUGHOUT THE WORLD pa

THE LIFE OF A TJR





A NEW JOINT REPLACEMENT

THE THOUGHTS ARE PUT DOWN ON PAPER

- A MANUFACTURER IS INVOLVED
- ALL ASPECTS OF THE DESIGN ARE DISCUSSED
- EQUIVALENCES ARE LISTED

ISO STANDARDS ARE OBSERVED



A NEW JOINT REPLACEMENT ISO STANDARDS

- INTERNATIONAL ORGANISATION FOR STANDARDIZATION
- www.iso.org/home.htm
- ISO creates <u>documents that provide requirements</u>, specifications, guidelines or characteristics that can be used consistently to ensure that materials, products, processes and services are fit for their purpose.
- We've published 22041 International Standards, which you can buy from our <u>members</u> or the <u>ISO Store</u>.
- Bringing real and measurable benefits to almost every sector imagineable, standards underpin the technology that we rely on and ensure the quality that we expect.



A NEW JOINT REPLACEMENT ISO STANDARDS

INTERNATIONAL ORGANISATION FOR STANDARDIZATION

AMIE...

HOW GOOD ARE THEY FOR JOINT REPLACEMENT?

- ARE THEY UP TO DATE AND RELIABLE
- DOES THE EU HAVE INPUT INTO THEIR DEVELOPMENT
- WHO VALIDATES THEM?



A NEW JOINT REPLACEMENT THE NEXT STEP

DISCUSSION WITHIN THE COMPANY

ADVICE AS TO HOW THEY PROCEED

WHERE CAN THEY GET ADVICE?



A NEW JOINT REPLACEMENT THE NEXT STEP At present

- SUBMISSION TO A NOTIFIED BODY
- ARE ALL NBS THE SAME?
- WHAT ARE THE RULES?

 WHERE DOES "EQUIVALENCE" FIT INTO THE PRESENT REGULATIONS?



A NEW JOINT REPLACEMENT THE NEXT STEP

 WHEN WILL THEY HAVE TO UNDERTAKE A CLINICAL EVALUATION

Do we know?

• WHERE DOES THE NEW EU PANEL FIT IN? WHO TRIGGERS IT Do we know?



THE NEXT STEP POST MARKET SURVEILLANCE

 I HAVE NEVER SEEN A UNVALIDATED PUBLICATION WHICH HAS INCLUDED A PMS STUDY LET ALONE A VALIDATED ONE

• WHY NOT?

WHAT IS ASKED FOR AT PRESENT?

WHAT WILL BE ASKED FOR IN THE FUTURE?



SUFFICIENT CLINICAL DATA

A DEBATE IN ITSELF!



WHAT MANY WOULD LIKE TO KNOW! NOW AND IN THE FUTURE

- HOW RIGOROUS SHOULD IT BE?
- WHAT SIZE OF COHORT
- FOR HOW LONG
- WHAT METRICS SHOULD BE USED
- HOW IS IT VALIDATED



THE TOOLS WE HAVE NOW AND IN THE FUTURE

- CLINICAL TRIALS
- RCTs ARE EXPENSIVE AND OFTEN NOT COMPLETED
- REGISTRIES ARE USUALLY MANDATORY
- EARLY REGISTRY DATA IS UNRELIABLE
- NOT ALL REGISTRY DATA HAS THE SAME RELIABILITY
- RSA STUDIES HAVE BEEN SHOWN TO ACCURATELY PREDICT EARLY FAILURE



THE TOOLS WE HAVE NOW AND IN THE FUTURE

- REGISTRIES CAN BE USED AS CONDUITS
- THEY CAN GENERATE QUESTIONS
- THEY CAN STORE ANSWERS



THE TOOLS WE HAVE NOW AND IN THE FUTURE

 RSA STUDIES HAVE BEEN SHOWN TO ACCURATELY PREDICT EARLY FAILURE

WHAT DOES IT INVOLVE?

 WE HAVE ONE OF THE WORLD'S EXPERTS HERE.... ROB, PLEASE GIVE US A MINUTE!



SHOULD RIGOR OF PMS DEPEND ON PERCEIVED RISK

NOW AND IN THE FUTURE

- EVALUATE RISK
- ? STEP BY STEP
- ? QUICK BLAST THEN STOP
- WHO DOES THE MONITORING?



SHOULD RIGOR OF PMS DEPEND ON PERCEIVED RISK

NOW AND IN THE FUTURE

IS BENCHMARKING AN OPTION?

- BENCHMARKING IMPLIES SETTING A STANDARD ACROSS ALL PRODUCTS
- BENCHMARKING USUALLY IMPLIES THE USE OF "NON INFERIORITY" CONCEPT



WHERE DO THE RESPOSIBILITIES LIE AND FOR HOW LONG?



 WHAT HAPPENS IF AN IMPLANT IS NOT DOING WELL IN ONE COUNTRY?

 WE SHOULD BE ABLE TO INTERROGATE ACROSS ALL EU COUNTRIES



NIMAC

NORE IMPLANT MONITORING ADVISORY COMMITTEE

IS THIS A GOOD IDEA?



A NEW JOINT REPLACEMENT HOW SHOULD IT BE INTRODUCED

SURGEONS NEED TO KNOW MANUFACTURERS NEED TO KNOW

ANSWERS PLEASE!

Developing the idea assessment	Pre CE testing	CE mark & Pre CE mark evalua	ntion Immediate Post market surveillar	nce Long term
Developer	_ISO Standards	—— Notified Body (NB)	Notified Body	
		-	"Beyond Compliance"	→
				ODEP and Joint Registries
,	The Regulator / Competent Authority			